Back

Clinical outcomes with the state-of-the-art PCI for the treatment of bifurcation lesions: A sub-analysis of the SYNTAX II study

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 3 - Coronary interventions - Stents Technique ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Rodrigo Modolo

Boston Scientific Corporation, Maple Grove (United States of America)

8 More presentations in this session

Presentation thumbnail
Preclinical evaluation of a bioresorbable vascular scaffold (BRS) on the reduction of neoatherosclerosis
Mr P. Nicol (Munich, DE)
Abstract Slides
Presentation thumbnail
Comparison of in-stent responses in 8 month between durable polymer and bioabsorbable polymer everolimus-eluting stent: serial observation with angioscopy and optical coherence tomography
Assistant Professor D. Kitano (Tokyo, JP)
Abstract
Presentation thumbnail
Vascular healing responses to paclitaxel coated balloon or everolimus eluting stent treatment in vessels with in-stent restenosis.
Doctor N. Gonzalo Lopez (Madrid, ES)
Abstract Slides
Presentation thumbnail
Impact of SYNTAX score on 5 years clinical outcomes in patients treated with cobalt-chromium everolimus-eluting stent for unprotected left main disease
Doctor T. Hiromasa (Kitakyushu, JP)
Abstract Slides
Presentation thumbnail
Long-term outcomes of unprotected left main coronary artery bifurcation lesions treated by second-generation drug-eluting stent implantation: 1-stent vs. 2-stent strategy
Doctor K. Osakada (Kurashiki, JP)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 3 - Coronary interventions - Stents

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
Percutaneous intervention is better than surgery in real life for most patients: pro
thumbnail
Congress Session
Complex PCI in practice: tips and tricks to take home
thumbnail
Congress Presentation
Prognostic impact of intravascular imaging in percutaneous coronary intervention according to atherothrombotic risk

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources